Table 1.

Baseline characteristics of the patients in the training and validation cohorts.

Clinicopathological variables	Training dataset (n = 151)			Clinicopathological variables	Validation dataset (n = 417)
	high-risk group	low-risk group	p		high-risk group	low-risk group	p
Age (years)			0.004	Age (years)			0.256
<60	33	51		<60	108	119
≥60	42	25		≥60	101	89
FAB classification			0.01	FAB classification			0.003
M0	10	5		M0	11	3
M1	20	15		M1	40	44
M2	15	23		M2	49	68
M3	4	11		M3	4	15
M4	10	19		M4	57	47
M5	12	3		M5	30	17
M6	2	0		M6	7	8
M7	1	0		M7	2	0
Gender			0.467	Status			0.001
Female	36	32		Alive	40	69
Male	39	44		Dead	169	139
Status			<0.0001	RUNX1-RUNX1T1			0.001
Alive	11	43		Negative	205	189
Dead	64	33		Positive	4	19
WBC			0.787	RUNX1 mutation			0.043
<10 × 109/L	28	30		Negative	153	157
≥10 × 109/L	47	46		Positive	37	21
BM blast			0.559
<70%	31	35
≥70%	44	41
Risk (Cytogenetic)			<0.0001
Good	7	24
Intermediate	43	38
Poor	24	12
ELN2017			<0.0001
Favorable	7	25
Intermediate	28	23
Adverse	36	17
Transplant			0.161
Yes	29	38
No	46	38
Chemotherapy			0.638
Yes	72	74
No	3	2
Relapse			0.12
Yes	38	29
No	36	46

FAB, French-American-British; WBC, white blood cell; BM, bone marrow; ELN, European LeukemiaNet.